Login
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC

galectintherapeutics.com

What Do They Do?

Develops carbohydrate-based drug candidates that target galectin proteins for patients with liver disease and certain cancers.

How Do They Make Money?

No revenue reported yet.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▲ +57% (Loss)
vs −$8.2M in Q3 FY2025
  • Aug 14, 2026 Galectin reached agreement with the FDA on planned Phase 3 trial design The company said it plans to submit the belapectin trial protocol in the third quarter of 2026.
  • Jun 23, 2026 FDA agreed on the path and primary endpoint for a planned Phase 3 trial Galectin said it is exploring strategic and financial partnerships to support belapectin's development.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support